Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 1-2/2010

01-06-2010 | Gastrointestinal Malignancies

Treatment Options for Surgically Resectable Gastric Cancer

Author: Lakshmi Rajdev, MD, MS

Published in: Current Treatment Options in Oncology | Issue 1-2/2010

Login to get access

Opinion statement

Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.
Literature
1.
Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.CrossRefPubMed
2.
Ajani JA: Chemotherapy for gastric carcinoma: new and old options. Oncology (Huntingt) 1998, 12(10 Suppl 7):44–47.
3.
Gunderson LL: Gastric cancer: patterns of relapse after surgical resection. Semin Radiat Oncol 2002, 12:150–161.CrossRefPubMed
4.
Gunderson LL, Sosin H: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982, 8:1–11.PubMed
5.
Landry J, Tepper J, Wood W, et al.: Analysis of survival and local control following surgery for gastric cancer. Int J Radiat Oncol Biol Phys 1986, 12:119.
6.
Landry J, Tepper J, Wood W, et al.: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990, 19:1357–1362.PubMed
7.
Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 1999, 230:170–178.CrossRefPubMed
8.
Viste A, Haugstvedt T, Eide GE, et al.: Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988, 207:7–12.CrossRefPubMed
9.•
Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer 1999, 79:1522–1530.CrossRefPubMed
10.•
Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004, 22:2069–2077.CrossRefPubMed
11.
McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph node dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003, CD001964
12.
Wolff A, Davidson N: Primary systemic therapy in operable breast cancer. J Clin Oncol 2000, 18:1558–1569.PubMed
13.
Ajani JA, Ota DM, Jessup JM: Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 1991, 68:1501–1506.CrossRefPubMed
14.
Ajani JA, Mayer RJ, Ota DM: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993, 85:1839–1844.CrossRefPubMed
15.
Ajani JA, Mansfield PF, Lynch PM: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999, 17:2403–2411.PubMed
16.
Hartgrink HH, van de Velde CJH, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer; long-term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004, 30:643–649.CrossRefPubMed
17.•
Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing perioperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol 2007, 25:18s (abstract 4510).
18.•
Zhang Z-X, Gu X-Z, Yin W-B, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC): report on 370 patients. Int J Radiat Oncol Biol Phys. 1998; 42:929-934.PubMed
19.
Fiorica F, Cartei F, Enea M, et al.: The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007, 33:729–740.CrossRefPubMed
20.
Ajani JA, Mansfield P, Janjan N, et al.: Multiinstitutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004, 22:2774–2780.CrossRefPubMed
21.
Ajani JA, Mansfield PF, Crane CH, et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23:1237–1244.CrossRefPubMed
22.••
Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11–20.CrossRefPubMed
23.•
Roth AD, et al.: Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Res (SAKK) and the European Institute of Oncology (EIO). World Congress of Gastrointestinal Cancers Barcelona, Spain, 2007
24.•
Earle C, Maroun J: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999, 35(7):1059–1064.CrossRefPubMed
25.•
Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000, 11(7):837–843.CrossRefPubMed
26.••
Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810–1820.CrossRefPubMed
27.•
Chu QS, Hammond LA, Schwartz G, et al.: Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004, 10(15):4913–4921.CrossRefPubMed
28.
Nakajima M, Fukami T, Yamanaka H, et al.: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006, 80:282–297.CrossRefPubMed
29.
Fujita K, Yamamoto W, Endo H, et al.: Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1. ASCO Meeting Abstracts 2007, 25:2504.
30.••
Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730.CrossRefPubMed
31.
Wagner AD, Grothe W, Haerting J, et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903–2909.CrossRefPubMed
32.•
Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Annual Meeting of ASCO 2009; abstract #LBA4509
33.
Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al.: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006, 15:65–71.PubMed
Metadata
Title
Treatment Options for Surgically Resectable Gastric Cancer
Author
Lakshmi Rajdev, MD, MS
Publication date
01-06-2010
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 1-2/2010
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-010-0117-1

Other articles of this Issue 1-2/2010

Current Treatment Options in Oncology 1-2/2010 Go to the issue

Lung Cancer

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

Alternative Therapies

Exercise Therapy in the Management of Solid Tumors

Lung Cancer

Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?

Gastrointestinal Malignancies

Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits